Marques Tiago 4

What Happened
Marques Tiago, CEO of Pasithea Therapeutics (KTTA), received a derivative option award for 1,756,069 shares on 2026-05-01. The reported acquisition price is $0.00, i.e., the filing records this as an award/derivative rather than an open‑market purchase. This is a grant of compensatory equity (not a sale) and is typically part of executive compensation.

Key Details

• Transaction date: 2026-05-01; Form 4 filed with the SEC on 2026-05-05 (Accession 0001213900-26-052262).
• Security: derivative option award covering 1,756,069 shares; reported price $0.00 per share.
• Vesting: 33% vests on the one‑year anniversary of the grant, remaining shares vest in equal quarterly installments over the next two years (total ~3-year vesting).
• Change in control: the award fully vests upon a Change in Control as defined in the plan.
• Post‑termination exercise: vested/exercisable shares may be exercised for up to 3 years after termination of continuous service, except if terminated for Cause.
• Shares owned after the transaction: not specified in the provided filing details.
• Footnote: grant made under the Issuer’s 2023 Stock Incentive Plan (as amended).

Context
This is a compensatory option award (derivative grant) to the CEO, not an open‑market purchase or sale. Such awards are common for executive incentives and include multi‑year vesting and change‑in‑control protections. Because it’s an award (not a sale), it does not directly signal buying or selling of the company’s shares on the open market.